Clinical Research Directory
Browse clinical research sites, groups, and studies.
CYTALUX for Intraoperative Imaging of Patients With Endometrial Cancer
Sponsor: Abramson Cancer Center at Penn Medicine
Summary
The research study is being done to assess the safety and ability of an investigational drug called CYTALUX (pafolacianine) and a special camera system for the detection of cancer in patients undergoing surgical resection for endometrial cancer.
Official title: Single Dose Investigator Initiated Pilot Study to Investigate CYTALUX (Pafolacianine) for Intraoperative Imaging of Patients With Endometrial Cancer Planned for Surgery
Key Details
Gender
FEMALE
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
10
Start Date
2025-10-18
Completion Date
2029-02
Last Updated
2025-12-12
Healthy Volunteers
No
Conditions
Interventions
CYTALUX™ (pafolacianine)
CYTALUX™ (pafolacianine) injection and standard care laparoscopic evaluation of disease. Intraoperative imaging with Cytalux will be performed for assessment of disease detection in patients who are being evaluated to undergo surgery for endometrial cancer. Any tissues removed as part of standard of care will undergo assessment with NIR light imaging prior to and after resection. This will be then compared to gold standard histologic confirmation by pathology.
1788 4K Camera System with Advanced Imaging Modality
Combination Product
Locations (2)
Abramson Cancer Center at Penn Medicine
Philadelphia, Pennsylvania, United States
University of Pennsylvania Gynecologic Oncology Department
Philadelphia, Pennsylvania, United States